Patents by Inventor Federico Cappuzzo

Federico Cappuzzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREDICTION OF CLINICAL OUTCOME TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS BY CANCER PATIENTS
    Publication number: 20170029901
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: August 9, 2016
    Publication date: February 2, 2017
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by non-small cell lung cancer patients
    Patent number: 9434994
    Abstract: Disclosed are methods to obtain an expression score to evaluate gene expression in a tissue specimen obtained from a person having or suspected of having cancer.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: September 6, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Jr., Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • METHODS FOR PREDICTION OF CLINICAL OUTCOME TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS BY CANCER PATIENTS
    Publication number: 20130004970
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: July 5, 2012
    Publication date: January 3, 2013
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Marileila Varella Garcia, Paul A. Bunn, JR., Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients
    Publication number: 20080090233
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR, protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: May 26, 2005
    Publication date: April 17, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch